Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, BBOT, ABVX, QQQ, EYPT, and represent 45.80% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 9 stocks: QQQ (+$154M), IWM (+$123M), XBI (+$122M), OLMA (+$69M), MLTX (+$31M), ASND (+$21M), ENGN (+$15M), ALMS (+$15M), COGT (+$8.0M).
- Started 6 new stock positions in XBI, ASND, QQQ, IWM, COGT, OLMA.
- Reduced shares in these 10 stocks: ABVX (-$81M), ACLX (-$64M), NAMS (-$41M), INSM (-$27M), CGON (-$25M), KRRO (-$22M), MTSR (-$21M), EWTX (-$18M), BBIO (-$15M), CNTA (-$15M).
- Sold out of its positions in ACLX, RNA, BMEA, CGON, ELVN, KRRO, MTSR.
- Cormorant Asset Management was a net buyer of stock by $133M.
- Cormorant Asset Management has $2.2B in assets under management (AUM), dropping by 49.22%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csvPortfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 35 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 12.9 | $280M | -5% | 950k | 294.74 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 10.4 | $224M | 18M | 12.52 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 8.4 | $182M | -30% | 1.4M | 134.85 |
|
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 7.1 | $154M | NEW | 250k | 614.31 |
|
| Eyepoint Com New (EYPT) | 7.0 | $151M | 8.3M | 18.27 |
|
|
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 5.7 | $123M | NEW | 500k | 246.16 |
|
| Spdr Series Trust State Street Spd Put Option (XBI) | 5.6 | $122M | NEW | 1.0M | 121.93 |
|
| Rapport Therapeutics (RAPP) | 4.2 | $92M | -5% | 3.0M | 30.34 |
|
| Bridgebio Pharma (BBIO) | 4.2 | $92M | -14% | 1.2M | 76.49 |
|
| Bright Minds Biosciences Com New (DRUG) | 3.8 | $83M | 1.1M | 78.04 |
|
|
| Edgewise Therapeutics (EWTX) | 3.8 | $82M | -18% | 3.3M | 24.82 |
|
| Olema Pharmaceuticals (OLMA) | 3.2 | $69M | NEW | 2.8M | 25.00 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.7 | $57M | +118% | 4.4M | 13.18 |
|
| Insmed Com Par $.01 (INSM) | 2.2 | $48M | -36% | 275k | 174.04 |
|
| Engene Holdings (ENGN) | 1.7 | $36M | +72% | 4.0M | 9.03 |
|
| Alumis (ALMS) | 1.6 | $36M | +69% | 3.6M | 9.76 |
|
| Mbx Biosciences (MBX) | 1.6 | $35M | -8% | 1.1M | 31.54 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $35M | -54% | 1.0M | 35.08 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.5 | $33M | -31% | 1.3M | 25.01 |
|
| Pharvaris N V (PHVS) | 1.4 | $30M | -20% | 1.1M | 27.75 |
|
| Bioage Labs (BIOA) | 1.2 | $27M | -4% | 2.0M | 13.23 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.0 | $21M | NEW | 100k | 213.24 |
|
| Tarsus Pharmaceuticals (TARS) | 0.9 | $21M | -16% | 250k | 81.88 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.9 | $19M | 2.3M | 8.14 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.8 | $17M | -32% | 1.3M | 12.70 |
|
| Oruka Therapeutics (ORKA) | 0.7 | $16M | 533k | 30.31 |
|
|
| Arcutis Biotherapeutics (ARQT) | 0.7 | $15M | -35% | 500k | 29.04 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.6 | $14M | -25% | 300k | 46.55 |
|
| Axsome Therapeutics (AXSM) | 0.6 | $14M | -25% | 75k | 182.64 |
|
| Cabaletta Bio (CABA) | 0.4 | $9.6M | -12% | 4.4M | 2.19 |
|
| Janux Therapeutics (JANX) | 0.4 | $9.0M | -23% | 650k | 13.80 |
|
| Cogent Biosciences (COGT) | 0.4 | $8.0M | NEW | 225k | 35.52 |
|
| Vaxcyte (PCVX) | 0.3 | $5.8M | -28% | 125k | 46.14 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.2 | $4.8M | -20% | 400k | 12.08 |
|
| Biohaven (BHVN) | 0.0 | $113k | 10k | 11.29 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2025 Q4 filed Feb. 17, 2026
- Cormorant Asset Management 2025 Q3 filed Nov. 14, 2025
- Cormorant Asset Management 2025 Q2 filed Aug. 14, 2025
- Cormorant Asset Management 2025 Q1 filed May 15, 2025
- Cormorant Asset Management 2024 Q4 filed Feb. 14, 2025
- Cormorant Asset Management 2024 Q3 filed Nov. 14, 2024
- Cormorant Asset Management 2024 Q2 filed Aug. 14, 2024
- Cormorant Asset Management 2024 Q1 filed May 15, 2024
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022
- Cormorant Asset Management 2022 Q2 filed Aug. 15, 2022
- Cormorant Asset Management 2022 Q1 filed May 16, 2022